Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial

IMPORTANCE: The current standard induction therapy for antineutrophil cytoplasm antibody (ANCA)–associated vasculitis is the combination of high-dose glucocorticoids and cyclophosphamide or rituximab. Although these regimens have high remission rates, they are associated with considerable adverse ev...

Full description

Saved in:

Bibliographic Details
Published in:	JAMA : the journal of the American Medical Association 2021-06, Vol.325 (21), p.2178-2187
Main Authors:	Furuta, Shunsuke, Nakagomi, Daiki, Kobayashi, Yoshihisa, Hiraguri, Masaki, Sugiyama, Takao, Amano, Koichi, Umibe, Takeshi, Kono, Hajime, Kurasawa, Kazuhiro, Kita, Yasuhiko, Matsumura, Ryutaro, Kaneko, Yuko, Ninagawa, Keita, Hiromura, Keiju, Kagami, Shin-ichiro, Inaba, Yosuke, Hanaoka, Hideki, Ikeda, Kei, Nakajima, Hiroshi
Format:	Article
Language:	English
Subjects:	Adverse events Alveoli Antibodies Antineutrophil cytoplasmic antibodies Clinical trials Cyclophosphamide Cytoplasm Glomerulonephritis Glucocorticoids Hemorrhage Immunotherapy Induction therapy Infections Monoclonal antibodies Original Investigation Patients Prednisolone Remission Remission (Medicine) Rituximab Vasculitis
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!